Blue Earth Diagnostics, a Bracco company, has announced a non-exclusive data-sharing agreement with Siemens Healthineers for anonymized clinical data and images from Blue Earth Diagnostics' Phase 3 LIGHTHOUSE trial in newly diagnosed prostate cancer. Siemens Healthineers will evaluate the data to enhance its analytics and artificial intelligence algorithms for prostate cancer image quantification and interpretation across its advanced PET/CT imaging software. The agreement will help streamline the PET/CT analytical workflow for hospitals and imaging centers by providing physicians with critical information for patient management and care. The data will be used to support the quantification and clinical interpretation of Blue Earth Diagnostics' radiohybrid prostate-specific membrane antigen (rhPSMA) agent, POSLUMA. The agreement builds on the companies' long-standing relationship and commitment to advancing healthcare through AI and innovative technologies.
Wed, 08 May 2024 12:29:16 GMT | Valdosta Daily Times